Article Text

PDF
FRI0301 A Phase I Pharmacokinetics TRIAL Comparing PF-06438179 (A Potential Biosimilar) and Infliximab in Healthy Volunteers (Reflections B537-01)
  1. C. Udata1,
  2. S.Y. Hua1,
  3. D. Yin1,
  4. S. Salts1,
  5. X. Meng2,
  6. M.I. Rehman3
  1. 1Pfizer Inc. San Diego, CA
  2. 2Pfizer Inc., San Diego
  3. 3Pfizer Inc., Cambridge, MA, United States

Abstract

Background PF-06438179, a proposed biosimilar to infliximab, has an identical primary amino acid sequence and similar physicochemical, in vitro, and in vivo functional properties to infliximab.

Objectives The Phase I study was designed to demonstrate pharmacokinetics (PK) similarity of PF-06438179 to infliximab sourced from the US (infliximab-US) and EU (infliximab-EU), and between infliximab-EU and infliximab-US. Safety was also evaluated.

Methods In this double-blind trial (NCT01844804), 151 healthy volunteers, 18-55 years old were randomized 1:1:1 to one of 3 treatment groups, of which 146 received a single 10 mg/kg IV dose of PF-06438179 (n=49), infliximab-US (n=48), or infliximab-EU (n=49). All subjects provided informed consent. PK was evaluated over a period of 8 weeks and safety and immunogenicity were assessed up to 12 weeks. PK similarity for a given test-to-reference comparison was considered to be demonstrated if the 90% CI of the test-to-reference ratio of the area under curve from time 0 to the last time point (AUCT), from time 0 to infinity (AUC0–∞), and maximum concentration (Cmax) were within the 80.00% – 125.00% bioequivalence (BE) acceptance window.

Results The baseline demographics for the 130 subjects evaluable for PK were similar among treatment groups. The 3 study drugs exhibited a similar PK profile, which is characterized by a rapid increase of serum drug concentration during infusion followed by a multi-phasic decline in drug concentrations (Figure). The 90% CI for the ratios of Cmax, AUCT, and AUC0–∞ were within the BE acceptance window of 80.00–125.00% for the comparisons of PF-06438179 to infliximab-US or infliximab-EU, and infliximab-EU to infliximab-US. Similar number of subjects experienced AEs among all 3 treatment groups. Overall the frequency and type of AEs reported were similar across all three treatment groups, although the number of AEs was highest in the infliximab-US group. The 3 treatments had a comparable ADA profile with a somewhat lower incidence of ADA response in the PF-06438179 group. No infusion related reactions were reported.

Conclusions This study demonstrates PK similarity of PF-06438179 to both infliximab-US and infliximab-EU and of infliximab-EU to infliximab-US. The 3 study drugs were generally safe and well-tolerated in this study.

Disclosure of Interest C. Udata Employee of: Pfizer Inc, S. Hua Employee of: Pfizer Inc, D. Yin Employee of: Pfizer Inc, S. Salts Employee of: Pfizer Inc, X. Meng Employee of: Pfizer Inc, M. Rehman Employee of: Pfizer Inc

DOI 10.1136/annrheumdis-2014-eular.5377

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.